Cardiovascular disease and lung cancer

被引：9

作者：

de Jesus, Mikhail ^{[1
]}

Chanda, Anindita ^{[2
]}

Grabauskas, Titas ^{[3
]}

Kumar, Manish ^{[4
]}

Kim, Agnes S. ^{[4
]}

机构：

[1] Univ Connecticut, Dept Cardiol, Hartford Hosp, Hartford, CT USA

[2] Univ Connecticut, Sch Med, Dept Internal Med, Farmington, CT USA

[3] Univ Connecticut, Sch Med, Farmington, CT USA

[4] Univ Connecticut, Pat & Jim Calhoun Cardiol Ctr, Dept Cardiol, Sch Med, Farmington, CT 06032 USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

cardiac adverse events; cardiotoxicities; lung cancer; non-small cell lung cancer; small cell lung cancer; chemotherapy; immunotherapy; 1ST-LINE TREATMENT; CARDIAC-DISEASE; PHASE-II; HYPERTENSION; EVENTS; RISK; PREVENTION; INHIBITORS; THERAPY; SMOKING;

D O I：

10.3389/fonc.2024.1258991

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related death. While survival rates have improved with advancements in cancer therapeutics, additional health challenges have surfaced. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with lung cancer. CVD and lung cancer share many risk factors, such as smoking, hypertension, diabetes, advanced age, and obesity. Optimal management of this patient population requires a full understanding of the potential cardiovascular (CV) complications of lung cancer treatment. This review outlines the common shared risk factors, the spectrum of cardiotoxicities associated with lung cancer therapeutics, and prevention and management of short- and long-term CVD in patients with non-small cell (NSCLC) and small cell (SCLC) lung cancer. Due to the medical complexity of these patients, multidisciplinary collaborative care among oncologists, cardiologists, primary care physicians, and other providers is essential.

引用

页数：10

共 91 条

[31] Cardiac Safety of Osimertinib: A Review of Data [J].

Ewer, Michael S. ;

Tekumalla, Sri Harsha ;

Walding, Andrew ;

Atuah, Kwame N. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) :328-+

[32]

Ewer Michael S, 2015, Cardiooncology, V1, P3, DOI [10.1186/s40959-015-0006-7, 10.1186/s40959-015-0006-7]

[33] Radiation-Induced Heart Disease [J].

Filopei, Jason ;

Frishman, William .

CARDIOLOGY IN REVIEW, 2012, 20 (04) :184-188

[34]

Franco Therese H, 2008, Ther Clin Risk Manag, V4, P1367

[35] Immune Checkpoint Inhibitor-Associated Myocarditis [J].

Ganatra, Sarju ;

Neilan, Tomas G. .

ONCOLOGIST, 2018, 23 (08) :879-886

[36]

Grundy SM, 2019, J AM COLL CARDIOL, V73, P3168, DOI [10.1016/j.jacc.2018.11.002, 10.1016/j.jacc.2018.11.003, 10.1161/CIR.0000000000000625]

[37] Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries [J].

Guha, Avirup ;

Jain, Prantesh ;

Fradley, Michael G. ;

Lenihan, Daniel ;

Gutierrez, Jahir M. ;

Jain, Chhavi ;

de Lima, Marcos ;

Barnholtz-Sloan, Jill S. ;

Oliveira, Guilherme H. ;

Dowlati, Afshin ;

Al-Kindi, Sadeer .

CANCER MEDICINE, 2021, 10 (12) :3862-3872

[38] Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger [J].

Handy, Catherine E. ;

Quispe, Renato ;

Pinto, Xavier ;

Blaha, Michael J. ;

Blumenthal, Roger S. ;

Michos, Erin D. ;

Lima, Joao A. C. ;

Guallar, Eliseo ;

Ryu, Seungho ;

Cho, Juhee ;

Kaye, James A. ;

Comin-Colet, Josep ;

Corbella, Xavier ;

Cainzos-Achirica, Miguel .

CIRCULATION, 2018, 138 (07) :727-734

[39]

[Anonymous], 2022, Circulation, V145, pe1033, DOI [10.1161/CIR.0000000000001063, 10.1161/CIR.0000000000001073]

[40] Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention [J].

Henriksen, Peter A. .

HEART, 2018, 104 (12) :971-977

← 1 2 3 4 5 6 7 8 9 10 →